Hepatic veno-occlusive disease (VOD) is one of the most common and important regimen-related toxicities observed after hematopoietic stem cell transplantation (HSCT). There are no universally accepted preventative or therapeutic approaches for VOD. We prospectively evaluated the safety and efficacy of a short course of methylprednisolone (MP) in 48 patients undergoing allogeneic HSCT who were diagnosed with hepatic VOD. MP was administered at a dose of 0.5 mg/kg i.v. every 12 h for a total of 14 doses, and then discontinued without taper. Thirty (63%) patients responded with a reduction in total serum bilirubin of 50% or more after 10 days of treatment. In univariate analysis, non-responders had a higher total bilirubin at the start of MP therapy, more weight gain, evidence of fungal infection and platelet refractoriness. High SGPT and early engraftment were significant factors among responders. Twenty-five of the 30 responders survived up to day þ 100, whereas all but three non-responders died within 100 days post-HSCT, for a probability of survival of 58% among responders and 10% for non-responders. Prospective comparative studies are needed to confirm the observed encouraging outcome of MP therapy for VOD.
Introduction
Hepatic veno-occlusive disease (VOD) is a clinical syndrome characterized by painful hepatomegaly, jaundice, ascites and fluid retention manifested by otherwise unexplained weight gain. [1] [2] [3] [4] VOD is an important regimen-related toxicity observed after hematopoietic stem cell transplant (HSCT). [1] [2] [3] [4] [5] [6] [7] [8] [9] VOD is usually diagnosed based on clinical findings. 3, 10, 11 Patients who meet all the criteria for VOD but have confounding causes of liver dysfunction, or meet only one of the criteria for VOD (jaundice or fluid retention), are considered to have liver dysfunction of uncertain etiology. 3, 10, 11 The course of VOD ranges from a mild reversible one to a severe syndrome associated with multiorgan failure. [1] [2] [3] [4] Treatment is usually supportive, as approximately half of the patients with uncomplicated VOD ultimately recover spontaneously. 12 The precise sequence of events leading to the development of VOD is unknown. Cytokines such as TNF-a and IL-1, which are produced by macrophages and other reticuloendothelial cells in response to cytotoxic therapy, infection, ionizing radiation and hypoxia have cellular effects, which suggest that they play a major role in the development of VOD. 1, [13] [14] [15] [16] [17] [18] Corticosteroids are potent inhibitors of cytokines and, therefore, could potentially have a role in the treatment of VOD. 1, 2, 13 In this study we have tested the safety and efficacy of the administration of a short course of methylprednisolone (MP) for the treatment of VOD.
Materials and methods

Study population
From January 1997 to December 2002, a total of 325 allogeneic HSCT procedures were performed at our center. Forty-eight (15%) patients were diagnosed as having hepatic VOD. The diagnosis of VOD was established based on the Seattle criteria that require the presence of two of the following before day 30 post transplantation: jaundice, hepatomegaly and/or right upper quadrant pain, ascites and/or unexplained weight gain. 3 Other causes of liver dysfunction were excluded by careful clinical and laboratory evaluation, including physical examination, hepatitis serology, routine cultures, fungal culture and liver sonography. At the same time, hepatic drug toxicity was always entertained as a possible differential diagnosis.
A liver biopsy and hepatic venous pressure gradient measurement were not routinely performed for all patients. The Bearman model was used to assess the severity of VOD. 19 
Treatment design
Once the patient was diagnosed with VOD, MP was administered at a dose of 0.5 mg/kg. i.v. every 12 h for a total of 14 doses, then discontinued without taper. Other concurrent therapies for VOD such as heparin, tPA, warfarin or non-steroidal anti-inflammatory drugs were not permitted. All patients received supportive care, including diuretics for fluid mobilization and narcotics for pain control as needed. Complications such as encephalopathy and/or single or multiorgan failure were managed according to standard medical practice.
Patient monitoring
In addition to history and physical examination, each patient was followed with serial laboratory studies including complete blood count, total serum bilirubin, alkaline phosphatase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase (SGPT), serum creatinine, blood urea nitrogen (BUN) and electrolytes, prothrombin time, activated partial thromboplastin time, fibrinogen, fibrinogen degradation product (FDP) and appropriate blood cultures. Blood glucose was monitored for the evidence of hyperglycemia, which was treated with insulin as necessary. Time of onset of VOD was defined as the first day the patient fulfilled the diagnostic criteria outlined above.
Evaluation of multiorgan failure (MOF) and major bleeding Patients were considered to have MOF if there was documentation of dysfunction of one other system in addition to the liver. Renal dysfunction was defined as a doubling of admission baseline creatinine or dialysis dependence; pulmonary dysfunction was defined by the need for supplemental oxygen and/or documentation of hypoxemia by arterial blood gas determination or the need for mechanical ventilation; and central nervous system dysfunction was defined by the attending physician documentation of confusion, lethargy, delirium and/or coma. Major bleeding was defined as any bleeding in the CNS or lung or requirement of X2 units of RBCs per day for two consecutive days.
Definition of response
Response to high-dose MP was defined as a reduction in total serum bilirubin by 50% or more within 10 days of the initiation of treatment as described by Bearman et al.
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Clinical improvement with fluid mobilization, weight reduction, improved coagulopathy and/or reduction of other organ dysfunction was not used to confirm response as traditional supportive therapies such as diuretics, dialysis and respiratory support may influence these parameters.
Evaluation of therapy-related complications
Known early toxicities of high-dose MP including hyperglycemia, hypertension, psychosis, sepsis, fungal infection and episode of severe bleeding were evaluated in all patients from the day MP started to day þ 100 or until death.
Statistical methods
Categorical variables were summarized as frequencies and percentages whereas continuous variables were presented as mean (s.d.) or median and range. Treatment duration and factors that may influence response to therapy were further compared in responders and non-responders using Fisher's exact test and the Mann-Whitney U-test for categorical and continuous variables, respectively. The Kaplan-Meier method was used to construct survival plots of time to death from VOD and survival curves were compared by the log-rank test. A P-value o0.05 was considered significant. Table 1 summarizes demographic characteristics, underlying diagnoses and transplantation information for the 48 patients who received MP for the treatment of VOD. GVHD prophylaxis consisted of CYA and short course of MTX (15 mg/m 2 on day 1, 10 mg/m 2 on days 3 and 6) for all patients. Acute GVHD was observed in 25% of patients at a median of 26 days (range 20-65) and was not significantly different between responders and non-responders (P ¼ 0.73) ( Table 2 ). Antimicrobial prophylaxis consisted of i.v. acyclovir in addition to oral fluconazole, which was routinely discontinued with the earliest sign of liver function abnormality. One patient was seropositive for hepatitis B virus and another patient was positive for hepatitis C virus. Seventy nine percent of all patients Abbreviations: Bu ¼ oral busulfan 1 mg/kg q6h Â 16 doses; Cy ¼ cyclophosphamide 60 mg/kg IV daily Â 2 days; TBI ¼ total body irradiation 1200 rads given in 6 fractions over 3 days.
Results
Patient characteristics
Steroid therapy for VOD following stem cell transplantation A Al Beihany et al were ABO compatible, while 21% had a major or minor ABO mismatch, with a similar distribution between responders vs non-responders.
Characteristics of VOD
These are shown in Table 2 . RUQ pain was documented in 32 (67%) patients. Ascites was documented radiologically in 24 (50%) patients and hepatomegaly in 43 (90%) patients. MOF was documented in 15 (31%) patients, with nine patients having organ dysfunction in four systems and six in three systems. Another 17 patients had single organ failure in addition to the hepatic VOD, including nine patients with renal failure, six with respiratory failure; one had cardiac failure and one had CNS toxicity (Table 2) .
Treatment with methylprednisolone
Methylprednisolone was started at a median of 13.5 days (range 3-34 days) post transplantation. The median interval from clinical diagnosis of VOD to the initiation of MP was 4 days (range 0-15). Nine patients were continued on MP at 1 mg/kg/day as GVHD prophylaxis as their CYA was put on hold due to increased serum creatinine or other side effects thought to be secondary to CYA.
Response
When assessed 10 days from the start of MP therapy, 30 (63%) patients responded. The total serum bilirubin in responding patients decreased from a median of 124 mmol/l (range 38-432) at the start of treatment to a median of 51 (range 21-288) 10 days after the start of therapy (P ¼ 0.018).
Predictors of response
Fifteen variables were examined by the Fisher's exact test for association with response (Table 2) . When compared to the responding patients, non-responders had a higher total bilirubin at the start of MP therapy, higher weight gain, greater likelihood of fungal infection and platelet refractoriness. High SGPT and earlier engraftment were observed among responders.
Therapy-related complications
Hyperglycemia (blood glucose 4200 mg/dl) was the main complication and was observed in 29 (60%) patients. Fourteen (29%) patients developed hypertension, which required pharmacologic intervention and one patient developed psychosis thought to be steroid-related. Additionally, MP could have been a contributing factor for sepsis, CMV reactivation and fungal infection observed in 8 (17%), 16 (34%), and 5 (10%) patients, respectively. However, the overall frequency of these infections was similar to their frequency in other allogeneic HSCT patients not receiving MP in our unit.
Survival
Twenty-five of the 30 responders survived to day þ 100; and of these, 15 were alive as of June 2004. All but three non-responding patients died within 100 days post-HSCT and one of those three died of relapse at 298 days. The other two are still alive at the time of this analysis; causes of death are shown in Table 3 . No mortality from VOD or other regimen-related toxicity was seen beyond day þ 100 with disease recurrence being the most common cause of late death. The probability of survival obtained using Kaplan-Meier method was 58% for the 30 MP responders and 10% for the 18 non-responders and this was statistically significant (P ¼ 0.0001).
Discussion
Our study shows 63% response to MP in patients with VOD within 10 days as measured by decline in bilirubin with 58% survival to day þ 100 without the evidence of VOD. This is encouraging given the compromised condition of this cohort of patients; 67% of whom had at least one other organ failure in addition to the liver. Independent of VOD, patients undergoing HSCT with the evidence of organ dysfunction in more than one system have been reported to have a much higher procedurerelated mortality. 21 The mortality of patients with VOD correlates with the severity of the syndrome and can be less than 10% in patients with mild VOD to greater than 90% in severe VOD. 10 In our study all except two patients with VOD and MOF died within 100 days of transplantation with progressive VOD and were among the non-responders.
We used a reduction in bilirubin of 50% or more as a surrogate marker for response to therapeutic intervention as has been used in other studies. 20 In our study patients, the bilirubin level peaked approximately 5 days after the initial rise; and among those who responded, it declined significantly within an average of 3 days from the initiation of therapy (mean 8 days, median 3 days). Among VOD patients treated only with supportive care, the peak bilirubin level was usually observed at an average of 10 days; and among responders, the bilirubin level returned close to baseline in approximately 10 days.
1 Based on the above, the rapid response observed in our study is less likely to represent spontaneous recovery and more likely to be the result of an effective intervention.
In univariate analysis, high serum bilirubin, percentage of weight gain, presence of fungal infection and platelet refractoriness were predictors of poor response. On the other hand, early engraftment and elevated serum SGPT were predictors of good response. Although it is possible that early engraftment helps in recovery and response of VOD to treatment, it is much more likely that patients responding to VOD treatment will have enhanced engraftment. The significantly higher incidence of fungal infection at the start of therapy among non-responders suggests that perhaps those with active fungal infections should not be considered for this treatment.
Treatment with this regimen was very well-tolerated with minimal side effects, and no serious sequel was documented. Transient steroid-induced hyperglycemia was the most frequently observed side effect seen in 34 (70%) of the patients and was well controlled with insulin. Hypertension was the next most frequent side effect and was observed in 14 (29%) of the patients; however, many other factors could have contributed to this side effect.
Khoury et al. 22 have used high-dose MP at a dose of 500 mg/m 2 every 12 h for six doses to treat hepatic regimenrelated toxicity in 28 patients, including 20 patients with VOD and eight patients with liver dysfunction of uncertain etiology. Overall, 17 patients (61%) responded to this treatment, including 12 patients with VOD, and five patients with liver disease of unknown etiology. At 100 days post-transplantation, hepatic regimen-related toxicity resolved in all 13 survivors who responded to high-dose MP and one non-responding patient. The result of the above study is consistent with the responses observed in our study, however our treatment regimen involved administration of MP at a much lower dose but for a longer duration. In a subsequent report from the same group, 23 regimen-related toxicity (RRT) was noted, and it was suggested that this treatment modality should be evaluated only in non-GVHD hepatic RRT.
The reported incidence of VOD in the literature ranges from 0 to 70% and the fatality rate can be as low as 3% in mild cases and approaching 100% by day þ 100 in the established severe VOD cases with multiorgan failure. 1, 4 The incidence observed at our center was 15%. The disparity in the reported incidence and severity of VOD is related to the inherent toxicity of different conditioning regimens, patient selection and definition of what constitutes VOD 1 as well as the lack of histologic confirmation of clinically defined cases as it also applies to our study.
Despite the progress that has been made toward understanding the pathophysiology of hepatic VOD, there is still a lack of a well-established prevention and therapeutic approach for this disease. The available approaches are limited both in number and efficacy, and some are associated with significant toxicity.
To date, the majority of the clinical trials that have evaluated a therapeutic intervention for the management of established VOD, including our study, have been uncontrolled. Thus, it is difficult to determine the independent effect of these interventions. Many variables besides therapeutic intervention may have contributed to the observed outcomes, including the fact that many studies, including ours, lack histologic confirmation of clinically defined cases to exclude the possibility of alternate diagnoses. These variables represent a significant challenge in the design of future prospective controlled trials to determine the potential efficacy of an agent or intervention used for the treatment of this disease.
